Form 4: Baker Bros. Advisors Sells KALA BIO Shares

Baker Bros. Advisors, a former 10% owner, significantly reduced its stake in KALA BIO, Inc. through multiple stock sales in late September and early October 2025.

Summary

• Baker Bros. Advisors LP, through its managed funds 667, L.P. and Baker Brothers Life Sciences, L.P., disposed of a total of 730,408 shares of KALA BIO, Inc. common stock.
• Transactions occurred on September 30, 2025, and October 1, 2025.
• On September 30, 2025, 21,376 shares were sold at a weighted average price of $1.5959 per share (ranging from $1.50 to $1.84), and 195,425 shares were sold at the same weighted average price.
• On October 1, 2025, 50,640 shares were sold at a weighted average price of $1.3838 per share (ranging from $1.27 to $1.48), and 462,967 shares were sold at the same weighted average price.
• Following these transactions, the reporting persons indirectly beneficially own 97,120 shares (through 667, L.P.) and 887,973 shares (through Life Sciences, L.P.) from the September 30 sales, and 46,480 shares (through 667, L.P.) and 425,006 shares (through Life Sciences, L.P.) from the October 1 sales.
• Julian C. Baker and Felix J. Baker, managing members of Baker Bros. Advisors (GP) LLC, may be deemed to have an indirect pecuniary interest in the reported common stock.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant selling by a major institutional investor and former 10% owner, which typically signals reduced confidence in the company's outlook.

Negatives

• A significant reduction in ownership by Baker Bros. Advisors, a prominent institutional investor and former 10% owner, could signal a lack of confidence in KALA BIO's future prospects.
• The sales occurred at declining weighted average prices, from $1.5959 to $1.3838, indicating a downward trend in the stock price during the selling period.

Industry Context

This filing reflects a significant institutional investor's decision to reduce its exposure to KALA BIO, Inc. Such actions by major shareholders can influence market perception and potentially impact the stock's performance relative to its peers in the biotechnology sector.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on the stock price due to the significant selling by a major institutional investor.
• Potential Investors: May view the reduction in stake by Baker Bros. Advisors as a cautionary signal, influencing investment decisions.

Key Dates

Recommendation

The substantial reduction in ownership by Baker Bros. Advisors, a sophisticated institutional investor and former 10% owner, indicates a significant loss of conviction in KALA BIO's stock. Such a move by a major player often precedes further declines or reflects underlying concerns not yet fully public. Investors should consider this a strong bearish signal and evaluate reducing their exposure.

Keywords

KALA BIO, KALA, Baker Bros. Advisors, Insider Selling, Beneficial Ownership, Stock Sale, Form 4, Institutional Investor